5AM Ven­tures: Fu­el­ing the Next Gen­er­a­tion of In­no­va­tors

Yesterday

I-Mab —A Biotech on the Rise with In­spired Sci­ence

3 weeks ago

Fos­ter­ing Re­silien­cy at the Cross­roads of Try­ing Times: A Tool­box for Em­ploy­ee Agili­ty

5 weeks ago

Hair­pins and Scis­sors - De­liv­er­ing a Non-Gene Edit­ed Al­lo­gene­ic CAR T Cell Ther­a­py for the Mass­es

Last month

Putting Da­ta to Work in a Pan­dem­ic

Last month

Clin­i­cal tri­al mon­i­tor­ing is about to change for­ev­er

Last month

Im­ple­ment­ing re­silience in the clin­i­cal tri­al sup­ply chain

Last month

Biotech IPOs: New Steps to Suc­cess on the Road to Go­ing Pub­lic

2 months ago

Evolv­ing Treat­ment Land­scape for NASH

2 months ago

How In­no­v­a­tive Tech­nolo­gies and a Ded­i­cat­ed Site Net­work is Dri­ving Pa­tient Re­cruit­ment for Biotech Clin­i­cal Tri­als in Aus­tralia

2 months ago

A new chap­ter in the de­cen­tral­ized clin­i­cal tri­al ap­proach

3 months ago

Solv­ing Phar­ma’s Da­ta Si­lo Prob­lem: Why a Link­able Da­ta In­fra­struc­ture is Good for Bio­phar­ma and Good for Pa­tients

3 months ago

How Clini­cReady by Aus­tralian CRO Avance Clin­i­cal de­liv­ers pre­clin­i­cal project man­age­ment and sci­en­tif­ic and reg­u­la­to­ry ad­vice to get biotechs in­to clin­ic faster

3 months ago

Mi­no­ryx and Sper­o­genix ink an ex­clu­sive li­cense agree­ment to de­vel­op and com­mer­cial­ize lerigli­ta­zone in Chi­na

3 months ago

Five Steps to Guide Suc­cess­ful Risk-Based De­cen­tral­ized Clin­i­cal Tri­als

4 months ago

Open & Flex­i­ble Tech­nol­o­gy Can En­able Break­through In­no­va­tion

4 months ago

The In­ge­nu­ity En­gine: Trans­la­tion­al Re­search and the Need for Speed

4 months ago

FSP and COVID-19: Im­pact on Clin­i­cal Tri­al De­vel­op­ment

5 months ago

Cell and Gene Con­tract Man­u­fac­tur­ers Must Em­brace Dig­i­ti­za­tion

5 months ago

Aus­tralia, home to a world-class ear­ly phase clin­i­cal tri­al ecosys­tem

6 months ago

Trans­port Sim­u­la­tion Test­ing for Your Ther­a­py is the Best Way to As­sure FDA Ex­pe­dit­ed Pro­gram Ap­proval

6 months ago

$48 Bil­lion Is Lost to Avoid­able Ex­per­i­ment Ex­pen­di­ture Every Year

7 months ago

BiTE® Plat­form and the Evo­lu­tion To­ward Off-The-Shelf Im­muno-On­col­o­gy Ap­proach­es

7 months ago

How Aus­tralia De­liv­ers Rapid Start-up and 43.5% Re­bate for Ear­ly Phase On­col­o­gy Tri­als

7 months ago
1234 Next page Last page